Core Viewpoint - Zhiyang Innovation Technology Co., Ltd. has shifted its strategy from planning to acquire a controlling stake in Shenzhen Lingming Photon Technology Co., Ltd. to making a strategic investment of 300 million yuan in cash, following a month-long suspension of its stock trading [2][3]. Group 1: Investment Details - Zhiyang Innovation signed a Strategic Investment Intent Agreement with Lingming Photon on February 25, planning to invest approximately 300 million yuan, which is expected to give Zhiyang a stake of about 9.09% to 10% in Lingming [3]. - The pre-investment valuation of Lingming Photon is estimated to be between 2.7 billion yuan and 3 billion yuan [3]. Group 2: Strategic Rationale - Lingming Photon is recognized as a high-quality provider of dToF (direct time of flight) sensor chips and system solutions, which aligns with Zhiyang's existing product offerings in industrial models, intelligent perception terminals, and intelligent drones [3]. - The collaboration is expected to create significant synergies in technology, supply chain, and market applications, enhancing Zhiyang's supply chain and R&D capabilities [3]. Group 3: Future Collaboration - The agreement outlines future cooperation in areas such as laser radar research and development, chip module procurement, and applications in intelligent inspection business [3][4]. - The partnership aims to leverage Zhiyang's extensive industrial data to provide tailored training samples for Lingming's dToF chips, facilitating rapid adaptation to specific industrial inspection needs [4]. Group 4: Governance and Control - Following the investment, Zhiyang is expected to become a significant shareholder with over 9% ownership, allowing it to nominate a director candidate and hold veto power over Lingming's overall sale [5][6]. - This arrangement is viewed as a strategic move to maintain influence without the risks associated with high ownership stakes, thus ensuring a prudent governance approach [6]. Group 5: Market Outlook - The initial strategic cooperation period is set for three years, with Lingming Photon projected to double its revenue by 2025, although it is still expected to operate at a loss [6].

同壁财经讯，企查查数据显示，根据《海南省人民医院2025年先进医疗设备更新项目（一）结果公告 （采购包1）》，上海联影医疗科技股份有限公司于2026年2月26日公告中标海南省人民医院采购项目， 中标金额为7000.00万元。 2025年上半年公司营业收入为60.16亿元，营业收入增长率为12.79%，归属母公司净利润为9.98亿元， 归属母公司净利润增长率为5.03%。 目前公司属于医疗保健行业，主要产品类型为诊断治疗设备，2024年报主营构成为销售医学影像诊断设 备及放射治疗设备:81.99%;提供维修收入:13.16%;其他业务:4.04%;软件收入:0.81%。 同壁财经讯，企查查数据显示，根据《海南省人民医院2025年先进医疗设备更新项目（一）结果公告 （采购包1）》，上海联影医疗科技股份有限公司于2026年2月26日公告中标海南省人民医院采购项目， 中标金额为7000.00万元。 相关上市公司：联影医疗(688271.SH) 同壁财经小贴士： 相关上市公司：联影医疗(688271.SH) 同壁财经小贴士： 联影医疗（688271.SH）2024年营业收入为103.00亿元，营业收入增长率为-9.73 ...

2月25日晚，智洋创新公告称，公司此前筹划以发行人民币普通股股票、定向发行可转换公司债券（如有）、支付现金（如有）等方式购买深圳市灵明光 子科技有限公司（简称"灵明光子"）控股权，同时拟募集配套资金。因交易双方未能就交易核心条款达成一致意见，经审慎研究，公司决定终止筹划本次 重大资产重组事项。公司股票自2月26日开市起复牌。 虽然重组止步，但智洋创新选择了另一种方式入股灵明光子，并有望与之开展深度合作。 智洋创新公告称，公司与灵明光子签署《战略投资意向协议》，拟以现金向灵明光子进行增资及购买部分股权（如有），投资金额初步暂定为3.00亿元。 灵明光子投前估值水平初步暂定为27亿元至30亿元。智洋创新投后持股比例为9.09%至10.00%。 智洋创新预计有权提名一名灵明光子的董事候选人，并拥有灵明光子的整体出售否决权。 第二，在智洋创新采纳灵明光子设计制造的激光雷达芯片及模组的前提下，由智洋创新向灵明光子采购激光雷达芯片及模组，并应用于智洋创新的雷视一 体化产品上。 第三，双方合力推动激光雷达搭载设备在智能巡检业务上的应用，力争形成相关技术方案的更新迭代。 第四，同等条件下优先选择对方进行资本和股权层面的合作， ...

2月16日，蚂蚁阿福以并不怎么"科技"的姿态登上了春晚舞台——某种程度上，机器人、通用AI代表的 是全球科技浪潮的顶点，而阿福则嵌入了一个生活化场景——老年人体检和慢病管理。 这是其占据用户心智的一个小节。 自去年12月至今，阿福让人们见识到，当顶级操盘手们想改变一个行业时，会做到什么地步。 只12月一个月，蚂蚁集团为阿福投入了"小几个亿"的市场推广费用。于是，严肃市场有各类KOL的花式 推介，下沉市场每个新用户下载APP会获得十几块钱红包，包括春晚在内，他们通过直接或间接的渠道 触达全人群。 无孔不入的线上宣传和线下地推，撑开了用户增长的一级漏斗。23日，蚂蚁阿福APP的总用户数突破1 亿大关，春节新增用户中52%来自三线及以下城市。 全面To C是这一轮AI技术与医疗碰撞的标志性故事。 蚂蚁阿福和百川智能在权衡后选择了直面用户。而如阿福这般高举高打的声势，让医院院长们回想起， 过去二十年里，支付宝是以怎样的决心和定力从各大银行和医疗信息化企业群雄割据的稳固江山里撕开 了院端线上支付的口子。 在上一个十年里，医疗AI更多面向的是B端市场，企业要想办法找渠道进医院，要绑定大放设备，要和 地方政府合作做普筛，要 ...

每经AI快讯，群益证券2月26日发布研报称，给予联影医疗（688271.SH）"买进(Buy)"评级。评级理由 主要包括：1）公司发布业绩快报，2025年共实现营收138.2亿元，同比+34.2%；归母净利润18.9亿元， 同比+49.6%，扣非后净利17.9亿元，同比+77.0%，公司业绩符合预期；2）国内继续受益于设备更新政 策持续落地，海外市场拓展强化。风险提示：地缘政治对海外市场的影响；国内采购进度变化影响；行 业监管政策影响。 （记者 王晓波） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 每经头条（nbdtoutiao）——超10万人挤爆服务器，围观8家房企抢"马场"：9小时竞价243轮，236亿元 成交！广州楼面价新地王诞生：8.5万元/㎡ ...

2026 年 02 月 26 日 王睿哲 C0062@capital.com.tw 目标价(元) 153 公司基本资讯 | 产业别 | | 医药生物 | | --- | --- | --- | | A 股价(2026/2/25) | | 127.45 | | 上证指数(2026/2/25) | | 4147.23 | | 股价 12 个月高/低 | | 164.36/116.93 | | 总发行股数(百万) | | 824.16 | | A 股数(百万) | | 824.16 | | A 市值(亿元) | | 1050.39 | | 主要股东 | | 联影医疗技术集 | | | | 团有限公司 | | | | (20.33%) | | 每股净值(元) | | 26.20 | | 股价/账面净值 | | 4.87 | | 一个月 | | 三个月 一年 | | 股价涨跌(%) | -3.4 | -3.4 -8.5 | | 近期评等 | | | | 日期 | 收盘价 | 评级 | | 2025-10-30 | 146.56 | 买进 | 产品组合 | 销售医学影像诊断设备 | 87.8% | | --- | --- ...

公司基本资讯 | 产业别 | | 医药生物 | | --- | --- | --- | | A 股价(2026/2/25) | | 127.45 | | 上证指数(2026/2/25) | | 4147.23 | | 股价 12 个月高/低 | | 164.36/116.93 | | 总发行股数(百万) | | 824.16 | | A 股数(百万) | | 824.16 | | A 市值(亿元) | | 1050.39 | | 主要股东 | | 联影医疗技术集 | | | | 团有限公司 | | | | (20.33%) | | 每股净值(元) | | 26.20 | | 股价/账面净值 | | 4.87 | | 一个月 | | 三个月 一年 | | 股价涨跌(%) | -3.4 | -3.4 -8.5 | | 近期评等 | | | | 日期 | 收盘价 | 评级 | | 2025-10-30 | 146.56 | 买进 | 产品组合 | 销售医学影像诊断设备 | 87.8% | | --- | --- | | 及放射治疗设备 | | | 维保服务 | 9.5% | | 软体业务 | 1.1% | 机构投资 ...

（联影医疗公告） 公司在报告期内营业总收入、营业利润、利润总额、归母净利润及归母净利润扣除非经常性损益的净利 润等多项指标的增幅均超过30%，主要得益于公司持续推出创新产品、提升高端产品市场认可度及优化 全球营销与服务体系。 近日，联影医疗发布公告称，2025年度公司实现营业总收入138.21亿元，同比增长34.18%；归母净利润 18.88亿元，同比增长49.60%。 ...

Policy Developments - Shandong Province held a meeting on February 25, 2026, to address corruption and misconduct in the healthcare sector, emphasizing the need for a coordinated effort to safeguard medical insurance funds and promote orderly development in healthcare [1] Drug and Device Approvals - Kanghong Pharmaceutical received approval from the National Medical Products Administration for clinical trials of KHN707 tablets for insomnia, a class 1 innovative drug [2] - Fosun Pharma's subsidiary received approval for clinical trials of Rumaine® (generic name: Luwomeitini tablets) for advanced non-small cell lung cancer, with global sales of MEK1/2 inhibitors projected to reach approximately $2.068 billion in 2024 [3] - China Pharmaceutical announced that its subsidiary received a drug registration certificate for injectable fosfomycin, aimed at treating acute bacterial skin and soft tissue infections [4] - Huyou Pharmaceutical received FDA approval for its new drug applications for Etoposide injection and Fluorouracil injection, enabling sales in the U.S. market [5] - Kangfang Biotech's application for the monoclonal antibody AK120 was accepted for review by the National Medical Products Administration [6] Industry Developments - Junshi Bioscience and Deqi Pharmaceuticals entered a strategic collaboration to explore the combined treatment potential of JS207 and ATG-037 for cancer patients in mainland China [8] - Illumina announced an 18-month innovation upgrade roadmap for the NovaSeq X sequencer, enhancing its capabilities and productivity [9] Capital Market Activities - Sainuo Medical announced a share repurchase plan with a total amount between 15 million and 30 million yuan, aimed at employee stock ownership plans or equity incentives [10] Financial Data - United Imaging reported a net profit of 1.888 billion yuan for 2025, a year-on-year increase of 49.60%, driven by new product launches and growth in overseas business [11] - Xiansheng Pharmaceutical projected a revenue of approximately 7.7 billion to 7.8 billion yuan for the 2025 fiscal year, with a net profit increase of 80.1% to 93.9% [12] - Sainuo Medical reported a net profit of 47.29 million yuan for 2025, a significant increase of 3,057.05% year-on-year, attributed to revenue growth and cost management [13]

Group 1: Economic Cooperation and Policies - The Chinese government expresses hope for the U.S. to view the implementation of the Phase One trade agreement objectively and rationally, urging against blame-shifting and provocations [1] - The Shanghai government has announced a reduction in housing purchase restrictions, including an increase in the maximum loan amount for first-time homebuyers from 1.6 million to 2.4 million yuan, with potential increases for families with multiple children [1] - The Guangzhou government is supporting financial product diversification to foster investment in technology and long-term projects [1] Group 2: Financial and Economic Forecasts - The International Monetary Fund (IMF) projects the U.S. GDP to grow by 2.6% in 2026, up from a previous forecast of 2.4% [3] - The Hong Kong government forecasts economic growth of 2.5% to 3.5% for the current year, with inflation rates expected at 1.7% and 1.8% respectively [1] - The "Inclusive Finance Prosperity Index" for January 2026 reached 49.60 points, indicating a slight increase, with financing conditions improving due to seasonal demand and policy support [1] Group 3: Company Announcements - Haiguang Information expects Q1 2026 revenue to be between 3.91 billion and 4.22 billion yuan, representing a year-on-year growth of 62.91% to 75.82% [1] - Transsion Holdings anticipates a 53.43% decline in net profit for 2025, down to 2.584 billion yuan [1] - Union Medical's net profit for 2025 is projected to increase by 49.60% to 1.888 billion yuan [1]